CN113395972A - 胎盘源性同种异体car-t细胞及其用途 - Google Patents

胎盘源性同种异体car-t细胞及其用途 Download PDF

Info

Publication number
CN113395972A
CN113395972A CN201980078364.2A CN201980078364A CN113395972A CN 113395972 A CN113395972 A CN 113395972A CN 201980078364 A CN201980078364 A CN 201980078364A CN 113395972 A CN113395972 A CN 113395972A
Authority
CN
China
Prior art keywords
cell population
cells
cell
peripheral blood
car
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980078364.2A
Other languages
English (en)
Chinese (zh)
Inventor
R·J·哈里里
K·卡拉谢维奇
李天剑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Human Longevity Inc
Original Assignee
Human Longevity Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Longevity Inc filed Critical Human Longevity Inc
Publication of CN113395972A publication Critical patent/CN113395972A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0605—Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/50—Cellular immunotherapy characterised by the use of allogeneic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
CN201980078364.2A 2018-11-30 2019-12-02 胎盘源性同种异体car-t细胞及其用途 Pending CN113395972A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862774142P 2018-11-30 2018-11-30
US62/774,142 2018-11-30
US201962878736P 2019-07-25 2019-07-25
US62/878,736 2019-07-25
PCT/US2019/064074 WO2020113234A1 (en) 2018-11-30 2019-12-02 Placenta-derived allogeneic car-t cells and uses thereof

Publications (1)

Publication Number Publication Date
CN113395972A true CN113395972A (zh) 2021-09-14

Family

ID=69005946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980078364.2A Pending CN113395972A (zh) 2018-11-30 2019-12-02 胎盘源性同种异体car-t细胞及其用途

Country Status (13)

Country Link
US (1) US20220118014A1 (https=)
EP (1) EP3886876A1 (https=)
JP (1) JP2022513164A (https=)
KR (1) KR20210111244A (https=)
CN (1) CN113395972A (https=)
AU (1) AU2019387571A1 (https=)
BR (1) BR112021010132A2 (https=)
CA (1) CA3120364A1 (https=)
MX (1) MX2021006402A (https=)
PH (1) PH12021551246A1 (https=)
SG (1) SG11202105217RA (https=)
WO (1) WO2020113234A1 (https=)
ZA (1) ZA202103263B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL293462A (en) * 2019-12-04 2022-07-01 Celularity Inc Placenta-derived allogeneic car-t cells and uses thereof
JP7846667B2 (ja) 2020-07-16 2026-04-15 レジェンド バイオテック アイルランド リミテッド Ｃｄ２０結合分子及びその使用
IL299867A (en) * 2020-07-16 2023-03-01 Nanjing Legend Biotech Co Ltd Cd19 binding molecules and uses thereof
US20250290039A1 (en) * 2023-07-10 2025-09-18 Pluri Biotech Ltd. Genetically engineered placental mucosalassociated invariant t (mait) cells and uses thereof

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
CN105408473A (zh) * 2013-05-14 2016-03-16 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
US20160144026A1 (en) * 2014-11-26 2016-05-26 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
US20160228547A1 (en) * 2015-02-06 2016-08-11 Batu Biologics, Inc. Chimeric antigen receptor targeting of tumor endothelium
CN106535934A (zh) * 2014-04-10 2017-03-22 西雅图儿童医院（Dba西雅图儿童研究所） 确定的组合基因修饰的t细胞产品
AU2015317316A1 (en) * 2014-09-19 2017-04-06 City Of Hope Central memory T cells for adoptive T cell therapy
CN107207598A (zh) * 2014-12-12 2017-09-26 蓝鸟生物公司 Bcma嵌合抗原受体
WO2018115887A1 (en) * 2016-12-21 2018-06-28 Ucl Business Plc Therapeutic cells
CN108366567A (zh) * 2015-05-26 2018-08-03 细胞结构公司 使用受刺激的胎盘干细胞的血管生成
CN108473957A (zh) * 2015-04-17 2018-08-31 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
EP2023717B1 (en) * 2006-05-11 2016-04-13 Anthrogenesis Corporation Methods for collecting placenta cord blood stem cells
CN105916521A (zh) * 2013-11-15 2016-08-31 人类起源公司 包含人胎盘灌注液细胞、其亚群的组合物及其用途
JP6797803B2 (ja) * 2014-12-31 2020-12-09 セルジーン コーポレイション ナチュラルキラー細胞を用いて血液障害、固形腫瘍、又は感染性疾患を治療する方法
US20160237407A1 (en) * 2015-02-17 2016-08-18 Batu Biologics, Inc. Universal donor chimeric antigen receptor cells
CA2992551A1 (en) * 2015-07-21 2017-01-26 Novartis Ag Methods for improving the efficacy and expansion of immune cells
AU2016323985B2 (en) * 2015-09-17 2022-12-15 Novartis Ag CAR T cell therapies with enhanced efficacy
JP7123794B2 (ja) * 2015-12-09 2022-08-23 メモリアル スローン ケタリング キャンサー センター 免疫細胞組成物及びそれを使用する方法

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105408473A (zh) * 2013-05-14 2016-03-16 得克萨斯州大学系统董事会 工程化嵌合抗原受体(car)t细胞的人应用
CN106535934A (zh) * 2014-04-10 2017-03-22 西雅图儿童医院（Dba西雅图儿童研究所） 确定的组合基因修饰的t细胞产品
AU2015317316A1 (en) * 2014-09-19 2017-04-06 City Of Hope Central memory T cells for adoptive T cell therapy
US20160144026A1 (en) * 2014-11-26 2016-05-26 Miltenyi Biotec Gmbh Combination immunotherapy of antigen-recognizing receptors and hematopoietic cells for the treatment of diseases
CN107207598A (zh) * 2014-12-12 2017-09-26 蓝鸟生物公司 Bcma嵌合抗原受体
US20160228547A1 (en) * 2015-02-06 2016-08-11 Batu Biologics, Inc. Chimeric antigen receptor targeting of tumor endothelium
CN108473957A (zh) * 2015-04-17 2018-08-31 诺华股份有限公司 改善嵌合抗原受体表达细胞的功效和扩增的方法
CN108366567A (zh) * 2015-05-26 2018-08-03 细胞结构公司 使用受刺激的胎盘干细胞的血管生成
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
WO2018115887A1 (en) * 2016-12-21 2018-06-28 Ucl Business Plc Therapeutic cells

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
沈柏均等: "人类脐血 基础与临床", 30 November 2016, 山东大学出版社, pages: 97 - 98 *

Also Published As

Publication number Publication date
KR20210111244A (ko) 2021-09-10
JP2022513164A (ja) 2022-02-07
ZA202103263B (en) 2024-09-25
US20220118014A1 (en) 2022-04-21
MX2021006402A (es) 2021-08-11
PH12021551246A1 (en) 2021-11-03
WO2020113234A1 (en) 2020-06-04
CA3120364A1 (en) 2020-06-04
SG11202105217RA (en) 2021-06-29
AU2019387571A1 (en) 2021-06-03
EP3886876A1 (en) 2021-10-06
BR112021010132A2 (pt) 2021-08-24

Similar Documents

Publication Publication Date Title
EP3194432B1 (en) Ror1 specific multi-chain chimeric antigen receptor
JP7604366B2 (ja) 遺伝子操作されたｔ細胞を作製するための方法
CN115052902B (zh) 淋巴细胞-抗原提呈细胞共刺激因子及其应用
CN112639083A (zh) 制备表达嵌合抗原受体的细胞的方法
JP2021534802A (ja) 複数のｈｌａ−ｇアイソフォームに対するキメラ抗原レセプター
US20180002427A1 (en) Cll1-specific multi-chain chimeric antigen receptor
KR20200069358A (ko) 키메라 항원 수용체 발현 세포의 제조 방법
JP2018500944A (ja) キメラ抗原受容体発現細胞の製造法
CN107074929A (zh) 嵌合自身抗体受体t细胞的组合物和方法
CA3002990A1 (en) Chimeric receptors containing traf-inducing domains and related compositions and methods
JP2018500006A (ja) 改変ｔ細胞における遺伝子発現の改変およびその使用
CN113395972A (zh) 胎盘源性同种异体car-t细胞及其用途
US20230108300A1 (en) Compositions and methods of t cell receptor vb family member targeting for the treatment of t cell associated disease
CN115835873A (zh) 用于产生表达重组受体的供体分批细胞的方法
WO2023023596A1 (en) Compositions and methods for chimeric antigen receptors specific to b cell receptors
CN114929341A (zh) 用于治疗髓系恶性肿瘤的嵌合抗原受体
US20220184124A1 (en) Methods and reagents for characterizing car t cells for therapies
US20250092363A1 (en) Placenta-derived allogeneic car-t cells and uses thereof
Çelik A Systemic comparison of different chimeric antigen receptor (car) designs for retargeting of NK-92 cells against tumor antigens
Özkazanç Ünsal Development of a novel in vitro screening method using genetically modified NK-92 cells against various tumor cells
KR20260013488A (ko) 면역 이펙터 세포 및 이의 용도
CN121399268A (zh) 工程化的滋养细胞及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information

Inventor after: R.J. Hariri

Inventor after: K. Karasevic

Inventor after: Li Tianjian

Inventor after: Ma Qiangzhong

Inventor after: Guo Wenzhong

Inventor after: Zhang Yanliang

Inventor after: Ji Hongjun

Inventor before: R.J. Hariri

Inventor before: K. Karasevic

Inventor before: Li Tianjian

CB03 Change of inventor or designer information